Cells surviving fractional killing by TRAIL exhibit transient but sustainable resistance and inflammatory phenotypes
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
When clonal populations of human cells are exposed to apoptosis-inducing agents, some cells die and others survive. This fractional killing arises not from mutation but from preexisting, stochastic differences in the levels and activities of proteins regulating apoptosis. Here we examine the properties of cells that survive treatment with agonists of two distinct death receptors, tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) and anti-FasR antibodies. We find that “survivor” cells are highly resistant to a second ligand dose applied 1 d later. Resistance is reversible, resetting after several days of culture in the absence of death ligand. “Reset” cells appear identical to drug-naive cells with respect to death ligand sensitivity and gene expression profiles. TRAIL survivors are cross-resistant to activators of FasR and vice versa and exhibit an NF-κB–dependent inflammatory phenotype. Remarkably, reversible resistance is induced in the absence of cell death when caspase inhibitors are present and can be sustained for 1 wk or more, also without cell death, by periodic ligand exposure. Thus stochastic differences in cell state can have sustained consequences for sensitivity to prodeath ligands and acquisition of proinflammatory phenotypes. The important role played by periodicity in TRAIL exposure for induction of opposing apoptosis and survival mechanisms has implications for the design of optimal therapeutic agents and protocols.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activators and target genes of Rel/NF-κB transcription factors
Pahl, H. L. (1999) · Oncogene · doi:10.1038/sj.onc.1203239 · Cited by 3,727
Luo, X., Budihardjo, I., Zou, H., Slaughter, C., & Wang, X. (1998) · Cell · doi:10.1016/s0092-8674(00)81589-5 · Cited by 3,626 · cited 1×
“MOMP allows the translocation of Smac and cytochrome c through pores into the cytosol (Luo et al., 1998; Li et al., 2002).”
BackgroundBacterial Persistence as a Phenotypic Switch
Balaban, N. Q., Merrin, J., Chait, R., Kowalik, L., & Leibler, S. (2004) · Science · doi:10.1126/science.1099390 · Cited by 2,952 · cited 1×
“Cell cycle genes comprise the largest class of genes down-regulated in survivor cells (and in IκBsr survivor cells; Supplemental Table S1), and slow growth rates were associated with drug resistance in previous studies (Balaban et al., 2004; Roesch et al., 2010; Sharma et al., 2010).”
ResultA Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Nature, Nurture, or Chance: Stochastic Gene Expression and Its Consequences
Raj, A., & van Oudenaarden, A. (2008) · Cell · doi:10.1016/j.cell.2008.09.050 · Cited by 2,593
Control of IκB-α Proteolysis by Site-Specific, Signal-Induced Phosphorylation
Brown, K., Gerstberger, S., Carlson, L., Franzoso, G., & Siebenlist, U. (1995) · Science · doi:10.1126/science.7878466 · Cited by 1,434 · cited 2×
“2186 | D. A. Flusberg et al. Molecular Biology of the Cell”
BackgroundMethodThe apoptosome: Signalling platform of cell death
Riedl, S. J., & Salvesen, G. S. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2153 · Cited by 1,097
Toll-like receptors and cancer
Rakoff-Nahoum, S., & Medzhitov, R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2541 · Cited by 925
Barnhart, B. C., Alappat, E. C., & Peter, M. E. (2003) · Seminars in Immunology · doi:10.1016/s1044-5323(03)00031-9 · Cited by 419
TAK1 activates AMPK‐dependent cytoprotective autophagy in TRAIL‐treated epithelial cells
Herrero‐Martín, G., Høyer‐Hansen, M., García‐García, C., Fumarola, C., Farkas, T., López‐Rivas, A., & Jäättelä, M. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.8 · Cited by 400 · cited 1×
“DR5 is believed to be the primary TRAIL receptor in MCF10A cells (Herrero-Martin et al., 2009), and we found MCF10A cells to be threefold more sensitive to saturating concentrations of anti-DR5 agonist antibodies than anti-DR4 antibodies (Pukac et al., 2005; Adams et al., 2008; Figure 7A, red and…”
BackgroundYes and PI3K Bind CD95 to Signal Invasion of Glioblastoma
Kleber, S., Sancho-Martinez, I., Wiestler, B., Beisel, A., Gieffers, C., Hill, O., Thiemann, M., Mueller, W., Sykora, J., Kuhn, A., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.02.003 · Cited by 309
Pukac, L., Kanakaraj, P., Humphreys, R., Alderson, R., Bloom, M., Sung, C., Riccobene, T., Johnson, R., Fiscella, M., Mahoney, A., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602487 · Cited by 306 · cited 1×
“We conclude that TRAIL and Fas induce a resistant state in surviving cells and that this state can be sustained by further TRAIL treatments even in the absence of cell death.”
BackgroundFricker, N., Beaudouin, J., Richter, P., Eils, R., Krammer, P. H., & Lavrik, I. N. (2010) · Journal of Cell Biology · doi:10.1083/jcb.201002060 · Cited by 154
Adams, C., Totpal, K., Lawrence, D., Marsters, S., Pitti, R., Yee, S., Ross, S., Deforge, L., Koeppen, H., Sagolla, M., et al. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402306 · Cited by 148 · cited 1×
“We conclude that TRAIL and Fas induce a resistant state in surviving cells and that this state can be sustained by further TRAIL treatments even in the absence of cell death.”
Background
Research works printed but not linked: 103
- Albeck JG, 2008, Mol Cell, 30, 11, 10.1016/j.molcel.2008.02.012 · DOI · Paper page
- Aldridge BB, 2011, Mol Syst Biol, 7, 553, 10.1038/msb.2011.85 · DOI · Paper page
- Ashkenazi A, 2008, Cytokine Growth Factor Rev, 19, 325, 10.1016/j.cytogfr.2008.04.001 · DOI · Paper page
- Ashkenazi A, 1999, Curr Opin Cell Biol, 11, 255, 10.1016/S0955-0674(99)80034-9 · DOI · Paper page
- Ashkenazi A, 2008, J Clin Invest, 118, 1979, 10.1172/JCI34359 · DOI · Paper page
- Austin CD, 2006, Proc Natl Acad Sci USA, 103, 10283, 10.1073/pnas.0604044103 · DOI · Paper page
- Banno T, 2004, J Biol Chem, 279, 32633, 10.1074/jbc.M400642200 · DOI · Paper page
- Banno T, 2005, J Biol Chem, 280, 18973, 10.1074/jbc.M411758200 · DOI · Paper page
- Bargmann CI, 1986, Cell, 45, 649, 10.1016/0092-8674(86)90779-8 · DOI · Paper page
- Barnhart BC, 2004, EMBO J, 23, 3175, 10.1038/sj.emboj.7600325 · DOI · Paper page
- Bhola PD, 2009, J Cell Sci, 122, 4296, 10.1242/jcs.055590 · DOI
- Boehm JS, 2007, Cell, 129, 1065, 10.1016/j.cell.2007.03.052 · DOI · Paper page
- Breitschopf K, 2000, J Biol Chem, 275, 21648, 10.1074/jbc.M001083200 · DOI · Paper page
- Brooks AD, 2010, Mol Cancer Res, 8, 729, 10.1158/1541-7786.MCR-10-0022 · DOI
- Chang DW, 2002, EMBO J, 21, 3704, 10.1093/emboj/cdf356 · DOI · Paper page
- Chaudhary PM, 1997, Immunity, 7, 821, 10.1016/S1074-7613(00)80400-8 · DOI · Paper page
- Chen L, 2010, Nature, 465, 492, 10.1038/nature09075 · DOI · Paper page
- Cohen AA, 2008, Science, 322, 1511, 10.1126/science.1160165 · DOI · Paper page
- Debnath J, 2003, Methods, 30, 256, 10.1016/S1046-2023(03)00032-X · DOI · Paper page
- Deng Y, 2002, Genes Dev, 16, 33, 10.1101/gad.949602 · DOI · Paper page
- Deveraux QL, 1997, Nature, 388, 300, 10.1038/40901 · DOI · Paper page
- Diessenbacher P, 2008, J Invest Dermatol, 128, 1134, 10.1038/sj.jid.5701141 · DOI
- Edgar R, 2002, Nucleic Acids Res, 30, 207, 10.1093/nar/30.1.207 · DOI · Paper page
- Ehrhardt H, 2003, Oncogene, 22, 3842, 10.1038/sj.onc.1206520 · DOI · Paper page
- Eldar A, 2010, Nature, 467, 167, 10.1038/nature09326 · DOI · Paper page
- Eskes R, 2000, Mol Cell Biol, 20, 929, 10.1128/MCB.20.3.929-935.2000 · DOI · Paper page
- Falschlehner C, 2007, Int J Biochem Cell Biol, 39, 1462, 10.1016/j.biocel.2007.02.007 · DOI · Paper page
- Feig C, 2007, EMBO J, 26, 221, 10.1038/sj.emboj.7601460 · DOI · Paper page
- Flusberg DA, 2013, Phys Biol, 10, 035002, 10.1088/1478-3975/10/3/035002 · DOI
- Frese-Schaper M, 2010, FEBS Lett, 584, 2867, 10.1016/j.febslet.2010.04.072 · doi:10.1016/j.febslet.2010.04.072
- Ganten TM, 2005, Hepatology, 42, 588, 10.1002/hep.20807 · DOI · Paper page
- Gaudet S, 2012, PLoS Comput Biol, 8, e1002482, 10.1371/journal.pcbi.1002482 · DOI · Paper page
- Gonzalvez F, 2010, Oncogene, 29, 4752, 10.1038/onc.2010.221 · DOI · Paper page
- Guicciardi ME, 2009, FASEB J, 23, 1625, 10.1096/fj.08-111005 · DOI · Paper page
- Gupta A, 2010, Proc Natl Acad Sci USA, 107, 14333, 10.1073/pnas.1000248107 · DOI · Paper page
- Gupta PB, 2011, Cell, 146, 633, 10.1016/j.cell.2011.07.026 · DOI · Paper page
- Harper N, 2003, J Biol Chem, 278, 44338, 10.1074/jbc.M307376200 · DOI
- Harper N, 2008, Methods Enzymol, 446, 293, 10.1016/S0076-6879(08)01618-2 · DOI
- Hellwig CT, 2008, J Biol Chem, 283, 21676, 10.1074/jbc.M802889200 · DOI · Paper page
- Hellwig CT, 2012, Mol Cancer Therapeut, 11, 3, 10.1158/1535-7163.MCT-11-0434 · DOI
- Hughes MA, 2009, Mol Cell, 35, 265, 10.1016/j.molcel.2009.06.012 · DOI · Paper page
- Ishimura N, 2006, Am J Physiol Gastrointest Liver Physiol, 290, G129, 10.1152/ajpgi.00242.2005 · DOI · Paper page
- Jang JH, 2008, Gut, 57, 492, 10.1136/gut.2007.137703 · DOI
- Jansen BJ, 2003, J Invest Dermatol, 121, 1433, 10.1046/j.1523-1747.2003.12636.x · DOI
- Jeremias I, 1998, Eur Cytokine Netw, 9, 687
- Johnstone RW, 2008, Nat Rev Cancer, 8, 782, 10.1038/nrc2465 · DOI · Paper page
- Kataoka T, 2004, Mol Cell Biol, 24, 2627, 10.1128/MCB.24.7.2627-2636.2004 · DOI · Paper page
- Kim JH, 2008, Biochem Biophys Res Commun, 377, 195, 10.1016/j.bbrc.2008.09.095 · DOI
- Kischkel FC, 1995, EMBO J, 14, 5579, 10.1002/j.1460-2075.1995.tb00245.x · DOI · Paper page
- Kohlhaas SL, 2007, J Biol Chem, 282, 12831, 10.1074/jbc.M700438200 · DOI
- Lane D, 2006, Mol Cancer Therapeut, 5, 509, 10.1158/1535-7163.MCT-05-0362 · DOI
- Lavrik IN, 2007, J Biol Chem, 282, 13664, 10.1074/jbc.M700434200 · DOI · Paper page
- Le Roy C, 2005, Nat Rev Mol Cell Biol, 6, 112, 10.1038/nrm1571 · DOI · Paper page
- Lee MW, 2005, Cancer Invest, 23, 586, 10.1080/07357900500283036 · DOI
- Li JH, 2003, J Immunol, 171, 1526, 10.4049/jimmunol.171.3.1526 · DOI · Paper page
- Li S, 2002, J Biol Chem, 277, 26912, 10.1074/jbc.M200726200 · DOI · Paper page
- Li Z, 2011, J Biol Chem, 286, 21164, 10.1074/jbc.M110.207571 · doi:10.1074/jbc.m110.207571
- Lin Y, 2000, Mol Cell Biol, 20, 6638, 10.1128/MCB.20.18.6638-6645.2000 · DOI · Paper page
- Luo JL, 2005, J Clin Invest, 115, 2625, 10.1172/JCI26322 · DOI · Paper page
- Malhi H, 2006, Oncogene, 25, 7333, 10.1038/sj.onc.1209765 · DOI
- Martin DA, 1998, J Biol Chem, 273, 4345, 10.1074/jbc.273.8.4345 · DOI · Paper page
- Mazurek N, 2011, Cell Death Differ, 19, 523, 10.1038/cdd.2011.123 · DOI
- Menke C, 2011, Cancer Res, 71, 1883, 10.1158/0008-5472.CAN-10-2252 · doi:10.1158/0008-5472.can-10-2252
- Muppidi JR, 2004, Immunity, 21, 461, 10.1016/j.immuni.2004.10.001 · DOI · Paper page
- Muranen T, 2012, Cancer Cell, 21, 227, 10.1016/j.ccr.2011.12.024 · DOI · Paper page
- Neumann L, 2010, Mol Syst Biol, 6, 352, 10.1038/msb.2010.6 · DOI · Paper page
- Opel D, 2011, Clin Cancer Res, 17, 3233, 10.1158/1078-0432.CCR-10-2530 · DOI · Paper page
- Rehm M, 2002, J Biol Chem, 277, 24506, 10.1074/jbc.M110789200 · DOI · Paper page
- Rehm M, 2006, EMBO J, 25, 4338, 10.1038/sj.emboj.7601295 · DOI · Paper page
- Rehm M, 2009, Cell Death Differ, 16, 613, 10.1038/cdd.2008.187 · DOI
- Roesch A, 2010, Cell, 141, 583, 10.1016/j.cell.2010.04.020 · DOI · Paper page
- Rossin A, 2009, Biochem J, 419, 185, 10.1042/BJ20081212 · DOI · Paper page
- Sabnis GJ, 2008, Cancer Res, 68, 4518, 10.1158/0008-5472.CAN-07-5999 · DOI · Paper page
- Santner SJ, 2001, Breast Cancer Res Treat, 65, 101, 10.1023/A:1006461422273 · DOI · Paper page
- Sayers TJ, 2006, Cancer Immunol Immunother, 55, 76, 10.1007/s00262-005-0676-3 · DOI
- Scaffidi C, 1999, J Biol Chem, 274, 1541, 10.1074/jbc.274.3.1541 · DOI · Paper page
- Sharp DA, 2005, J Biol Chem, 280, 19401, 10.1074/jbc.M413962200 · DOI · Paper page
- Siegel RM, 1999, J Allergy Clin Immunol, 103, 729, 10.1016/S0091-6749(99)70412-4 · DOI
- Sigal A, 2006, Nature, 444, 643, 10.1038/nature05316 · DOI · Paper page
- Singh DK, 2010, Mol Syst Biol, 6, 369, 10.1038/msb.2010.22 · DOI · Paper page
- Son JK, 2010, Cell Death Differ, 17, 1288, 10.1038/cdd.2010.9 · DOI
- Song JH, 2007, Cancer Res, 67, 6946, 10.1158/0008-5472.CAN-06-3896 · DOI · Paper page
- Song JJ, 2007, J Biol Chem, 282, 319, 10.1074/jbc.M608065200 · DOI
- Song JJ, 2009, Cell Signal, 22, 377, 10.1016/j.cellsig.2009.10.007 · DOI · Paper page
- Song JJ, 2010, Cell Signal, 22, 553, 10.1016/j.cellsig.2009.11.012 · doi:10.1016/j.cellsig.2009.11.012
- Spencer SL, 2009, Nature, 459, 428, 10.1038/nature08012 · DOI · Paper page
- Sun BK, 2010, Int J Oncol, 38, 249
- Sun BK, 2010, Oncol Rep, 25, 537
- Sun XM, 2002, J Biol Chem, 277, 11345, 10.1074/jbc.M109893200 · DOI · Paper page
- Takeda K, 2002, J Exp Med, 195, 161, 10.1084/jem.20011171 · DOI · Paper page
- Tang W, 2009, FEBS J, 276, 581, 10.1111/j.1742-4658.2008.06809.x · DOI
- Tang Z, 2006, Mol Cell Biol, 26, 5588, 10.1128/MCB.00199-06 · DOI
- Trauth BC, 1989, Science, 245, 301, 10.1126/science.2787530 · DOI · Paper page
- Trauzold A, 2006, Oncogene, 25, 7434, 10.1038/sj.onc.1209719 · DOI · Paper page
- Varfolomeev E, 2005, J Biol Chem, 280, 40599, 10.1074/jbc.M509560200 · DOI · Paper page
- Wagner KW, 2007, Nat Med, 13, 1070, 10.1038/nm1627 · DOI · Paper page
- Wajant H, 2003, Cytokine Growth Factor Rev, 14, 53, 10.1016/S1359-6101(02)00072-2 · DOI · Paper page
- Wilson NS, 2009, Nat Immunol, 10, 348, 10.1038/ni.1714 · DOI · Paper page
- Yan J, 2013, Cell, 152, 304, 10.1016/j.cell.2012.12.021 · DOI
- Yoshida T, 2009, Mol Cancer Res, 7, 1835, 10.1158/1541-7786.MCR-09-0244 · DOI
- Zauli G, 2005, J Cell Physiol, 202, 900, 10.1002/jcp.20202 · DOI
- Zhang L, 2005, Cancer Gene Ther, 12, 228, 10.1038/sj.cgt.7700792 · DOI · Paper page
- Zhang Y, 2009, Cancer Biol Ther, 8, 917, 10.4161/cbt.8.10.8141 · DOI
Cited by
The Coming Decade of Cell Death Research: Five Riddles
Green, D. R. (2019) · Cell · doi:10.1016/j.cell.2019.04.024 · Cited by 566
Cell-to-cell variation in p53 dynamics leads to fractional killing.
Paek, A. L., Liu, J. C., Loewer, A., Forrester, W. C., & Lahav, G. (2016) · Cell · doi:10.1016/j.cell.2016.03.025 · Cited by 292
The recurrent architecture of tumour initiation, progression and drug sensitivity
Califano, A., & Alvarez, M. J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.124 · Cited by 204
Surviving apoptosis: life–death signaling in single cells
Flusberg, D. A., & Sorger, P. K. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.03.003 · Cited by 149
Self-citationFallahi‐Sichani, M., Moerke, N. J., Niepel, M., Zhang, T., Gray, N. S., & Sorger, P. K. (2015) · Molecular Systems Biology · doi:10.15252/msb.20145877 · Cited by 99
“This is particularly true in the case of apoptosis, which is an all-or-none change in cell fate (Flusberg et al, 2013).”
Self-citation
Metadata
- Authors
- Flusberg, D. A., Roux, J., Spencer, S. L., & Sorger, P. K.
- Venue
- Molecular Biology of the Cell
- Published
- 2013-07-15
- Volume
- 24
- Issue
- 14
- Pages
- 2186-2200
- ISSN
- 1059-1524 (ISSN-L)
- 1939-4586
- OpenAlex
- W2132672330
- Cited by
- 96
- References
- 14
- FWCI
- 4.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.